Laparoscopy is commonly performed as a daycase procedure and requires satisfactory but brief and readily reversible muscle relaxation with good intubating conditions. We have examined the use of the new nondepolarizing muscle relaxant, mivacurium, in this setting and compared it with the two most commonly used such drugs in day surgery, atracurium and vecuronium, in a prospective randomized trial of 107 patients. Mivacurium provided a significantly more rapid onset and briefer duration of muscle relaxation, which was readily reversible with or without pharmacological antagonism.
With the advent of daycase surgery, there is a continuing challenge to develop new neuromuscular blocking agents. A particular goal is to find a nondepolarizing blocking agent with rapid onset and short duration that would be especially useful for brief surgical procedures and for endotracheal intubation. One such agent, mivacurium, appears to meet many of the criteria for a short-acting blocking agent 1 . Mivacurium has been shown to have a similar quality of neuromuscular blockade to atracurium and vecuronium, the drugs most commonly used when neuromuscular blockade for short periods is required 2, 3 . However, it appears that recovery from paralysis is more rapid after mivacurium 4 and such enhancement of neuromuscular block has obvious advantages for daysurgery anaesthesia.
The optimal model for daysurgery anaesthesia in which such a relaxant would be studied includes induction with propofol. Propofol anaesthesia has been shown to be appropriate for daycase surgery 5 with improved postoperative recovery and faster recovery of consciousness when compared with thiopentone in gynaecological patients 6 . Although the use of volatile agents may prolong the duration of action of muscle relaxant drugs, especially with vecuronium and mivacurium 10, 11 , with the relatively small concentrations of volatile agent used for short surgical procedures this phenomenon is unlikely to have been clinically significant.
The present study was designed to evaluate the onset, depth, effective duration of and recovery from neuromuscular block and the ease of intubation after the administration of mivacurium, compared with atracurium and vecuronium, in daycase surgical patients during propofol and nitrous oxide/oxygen/ enflurane anaesthesia for elective laparoscopy.
PATIENTS AND METHODS
All patients presenting for elective laparoscopic procedures in daysurgery were eligible for inclusion. There were no other criteria for inclusion.
The criteria for exclusion were age less than 18 years or greater than 60 years; pregnancy or risk of pregnancy; neurological or neuromuscular disorders; clinically significant hepatic, renal, cardiovascular, respiratory or psychiatric disorders; history of alcoholism and/or drug abuse; any significant history of oesophageal reflux; anatomical characteristics associated with difficult intubation; personal or family history of malignant hyperthermia or unusual sensitivity to neuromuscular drugs; exposure to antibiotics (other than the penicillins, tetracyclines or cephalosporins), quinidine, lignocaine, antihistamines (H1 or H2 blockers), or trimetaphan within 48 hours prior to the study, or planned exposure to these drugs during the study period, or exposure to antidepressants, carbamazepine or phenytoin within one week prior to the study; previous entry into this trial or another investigational trial within 30 days prior to this study. The formal trial protocol was approved by the institutional Ethics Committee, and the study was conducted under the Clinical Trial Notification (CTN) scheme. Formal acknowledgement of the trial was received from the Therapeutic Goods Administration (TGA). All patients gave written informed consent prior to entering the study.
The patients were randomized, after entry according to a computer-generated random number sequence, into three groups to receive either mivacurium, vecuronium or atracurium after induction of anaesthesia. All patients were unpremedicated. Anaesthesia was induced with propofol 2.5 mg/kg and fentanyl 2 µg/kg followed by either mivacurium 0.15 mg/kg, vecuronium 0.05 mg/kg or atracurium 0.3 mg/kg. These doses of muscle relaxant had been established after preliminary studies to determine which doses would provide relaxation of equiduration, such that after 20 minutes of operating time there were two responses on train-of-four stimulation, i.e. a reversible block. Anaesthesia was maintained with nitrous oxide/oxygen (2:1) with supplementary enflurane as required. Routine monitoring with ECG, non-invasive blood pressure measurement, pulse oximetry and end-tidal capnography was performed during anaesthesia.
The activity of the adductor pollicis brevis muscle in response to ulnar nerve stimulation was recorded with an electromyograph (Relaxagraph, Datex, Finland). Both single twitch and train-of-four stimuli were used as appropriate. At the end of the operation, enflurane was discontinued and neuromuscular block was reversed with atropine 1.2 mg and neostigmine 2.5 mg. Extubation was carried out when spontaneous respiration was considered adequate and when sufficient time had elapsed for T1:T0 to be at least 25% or after three minutes, which ever was the shorter time. As anaesthesia was discontinued at the end of the procedure rather than awaiting complete recovery of neuromuscular function, the standard pharmacological marker of recovery to a T1/T0 ratio >75% (rather than 90%) was used as a major recovery end-point for the study.
Neuromuscular function was assessed by: (a) evaluation of ease of intubation, graded as:
1. Excellent (easy passage of tube without coughing or bucking). 2. Good (passage of tube with slight coughing or bucking or both). 3. Poor (passage of tube with moderate coughing or bucking or both). 4. Not possible. (b) electromyographic record of muscle activity intraoperatively 12 , (c) handgrip strength measured with a dynamometer pre-and postoperatively 12 , (d) the time until a sustained headlift of at least five seconds could be achieved during recovery, (e) patient responses to telephone questionnaire on the following day concerning post-anaesthetic problems, especially any difficulty with walking or swallowing or any diplopia. Statistical analyses were made on an intention-totreat basis. For overall between-drug comparisons, χ 2 tests were used for dichotomous variables and Anova tests for continuous variables, except for postoperative grip strength for which analysis of covariance was used with preoperative grip strength as the covariate. To avoid false positive (type I) errors arising from multiple single drug comparisons, direct single drug comparisons were made only when the overall between-drug comparisons were significant. All analyses were made using the SPSSX package of a VAX Cluster network.
RESULTS
Of the 107 patients, 35 were randomized to receive atracurium, 35 to vecuronium and 37 to mivacurium. Their mean age was 34 years (range 16-94 yr), weight 63 kg (SD 11 kg), height 160 cm (SD 7 cm), heart rate 76/min (SD 10/min), BP 112/72 mmHg (SD 11/9 mmHg), temperature 36.4°C (SD 0.4°C); 89% were Caucasian, 29% had suffered a previous allergic reaction and 20% were on preoperative medication. Underlying disorders were pelvic or abdominal pain (44%), sterilization (33%), infertility (16%), endometriosis (6%) and postmenopausal bleeding (1%). There were 227 laparoscopic procedures, including laparoscopy alone (75), dilatation and curettage (62), tubal ligation (33), dye studies (20), hysteroscopy (19) and miscellaneous (18). The mean duration of the surgical procedure was 24.7 min (SD 10.5 min). There were no significant differences between the three treatment groups for any of these parameters.
Induction of anaesthesia was with propofol (163±32 mg) and fentanyl (120±28 µg), with N 2 O administration commencing 1.1±0.7 min after the start of induction. Anaesthesia was maintained with N 2 O 3.4±1.2 l/min, O 2 37±11% and enflurane 1.6±1.0%. All values are mean±SD. Antiemetics were given in 51 cases, analgesics in 25, antibiotics in two and oxytocin in two. There were no significant differences between the three treatment groups for any of these aspects of anaesthesia or drug administration.
Intubation was undertaken 195±39 sec (mean± SD) after muscle relaxant injection and was graded as excellent in 77%, good in 17% and poor in 3% of cases, with a success rate at first attempt of 96%. There were no significant differences between the three treatment groups for any of these aspects of intubation. However, the degree of block at the start of intubation was significantly greater after mivacurium (88±13) than after atracurium (69±28) or vecuronium (73±27) (mean±SD, P<0.001).
Neuromuscular monitoring showed significantly shorter times to maximum depression and to each recovery level after mivacurium compared with either atracurium or vecuronium ( Table 1 and Figure 1 ). Virtually all patients (97 in total, i.e. 91%, and not different between the three treatment groups) reached the planned major recovery end-point of T1/T0 ratio >75%. The required intention-to-treat analysis thus gave results which were also comparable to an efficacy analysis.
The times from induction of anaesthesia to admission to the post-anaesthetic care area (32.6±12.4 min) and to discharge from the post-anaesthetic care area (73±19 min) (all values mean±SD) were not significantly different between the three treatment groups.
Grip strength measured on arrival in the postanaesthetic care area and 5, 10, 15, 25, 35, 45 and 60 min afterwards showed no significant differences between the three treatment groups, whether corrected or uncorrected for the preoperative value. Similarly, there were no differences for headlift during recovery, with 92% being able to achieve at least five seconds on arrival in the post-anaesthetic care area and all patients being able to do so within 15 minutes.
Follow-up next day was successful in 94% of patients and 89% of these had no clinical complaints; twelve patients reported minor physical discomfort, with no significant differences between the three treatment groups.
Adverse drug-related experiences were recorded in four patients. After mivacurium, one had facial flushing and one bradycardia; after atracurium, one had 135 
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DISCUSSION
The ideal neuromuscular blocking drug for daysurgery procedures should provide adequate paralysis for easy endotracheal intubation within a clinically acceptable time of onset (<3 min), be capable of rapid pharmacological antagonism if required, have minimal side-effects, be non-cumulative on repeat dosing, and have a short duration of action (15-20 min) . In addition, laparoscopy demands greater flexibility in use from a neuromuscular blocking drug than do most other operations, since the operating time can vary from 10 minutes to 45 minutes or more, and the completion of the operation can be relatively sudden and unexpected.
Suxamethonium provides ideal conditions in many ways but has several drawbacks, including the problems of atypical plasma cholinesterase, the risk of phase II block with higher doses, postoperative muscle pain and the rare association with malignant hyperpyrexia 3 . The intermediate nondepolarizing blocking drugs, vecuronium and atracurium and perhaps especially mivacurium, also possess many of the ideal characteristics. In addition, mivacurium has a shorter duration of action than any other currently used nondepolarizing agent, though it is metabolized by human plasma cholinesterase, thus sharing one potential disadvantage of suxamethonium 1 . It should therefore be more suitable for short surgical procedures than vecuronium or atracurium, and furthermore, pharmacological antagonism may not be required.
In the present study we have demonstrated that mivacurium provides significantly faster neuromuscular blockade than either vecuronium or atracurium, thus facilitating rapid intubation. The desired recovery end-point of T1/T0 ratio >75% was achieved in virtually all patients, with recovery after mivacurium being significantly faster than after either vecuronium or atracurium. Moreover, it is apparent that recovery from neuromuscular blockade even prior to pharmacological reversal is very rapid after mivacurium. However, overall recovery and time taken until discharge from the post-anaesthetic care area were the same for all three drugs.
The duration of action of mivacurium has been shown to be closer to that of suxamethonium than to that of atracurium 4 , so that mivacurium may offer an alternative to suxamethonium for production of profound neuromuscular block of short duration, and without the necessity for pharmacological reversal (although neostigmine does provide ready an-tagonism of mivacurium). Thus the myalgia, hyperkalaemia and bradycardia which may be associated with suxamethonium can be avoided in clinical situations where its more rapid onset of action is not required.
Establishment of an appropriate and reliable equiduration dose of mivacurium may be difficult. In the present study, though not in others 15 , the onset of neuromuscular block was significantly shorter than for either vecuronium or atracurium. However, in accord with these other studies 15 , we confirmed that the duration of blockade was shorter and the various recovery stages significantly more rapid than for either vecuronium or atracurium. Importantly, the uncommon but unpredictable phenomenon of prolonged neuromuscular blockade has been reported, even after the recommended dose of mivacurium, in about 5% of patients and especially in those with abnormal or absent plasma cholinesterase 8, 9 . In such situations, reversal may not necessarily be enhanced by acetylcholinesterase antagonism. On the other hand, since 5 to 10% of the population have an increased plasma cholinesterase activity, the dose of mivacurium required to produce full paralysis and ideal intubating conditions will be higher in such patients than anticipated from average population studies. For this reason, the initially recommended dose of 0.15 mg/kg has been superseded by a currently recommended dose of 0.2 to 0.25 mg/kg. Variations in plasma cholinesterase activity between individuals may explain both the differences in study results with different populations and the reportedly unpredictable action of mivacurium, though in the present study the variability of action of mivacurium was in fact consistently less than with either vecuronium or atracurium. Although monitoring of neuromuscular blockade improves the safety and reliability of administration of all neuromuscular blocking drugs 14 , the optimal use of mivacurium in particular may require continuous infusion.
We conclude that mivacurium provides a more rapid onset of and recovery from neuromuscular blockade than either vecuronium or atracurium, thus enhancing conditions both for endotracheal intubation and for later extubation after short procedures.
